دراسة بعض المتثابتات المخبرية للتمييز بين الأمراض المعوية العضوية و متلازمة القولون المتهيج

الملخص EN

The diseases that contribute colonic movement disorder, especially diarrhea, can be divided into diarrhea and abdominal pain from an inflammatory origin caused by an immune response in the mucosal layer in the bowel which know as inflammatory bowel disease (IBD), and diarrhea and abdominal pain from neuro psychological origin known as irritable bowel syndrome (IBS).

The Calprotectin, which consists 60% of neutrophil cytoplasm, and the CRP, one of the most important acute inflammation phase markers, can play an important role in detection of IBD.

Since there is no single laboratory test with high accuracy to discriminate Between IBD and IBS, and the golden criteria is colon endoscopy with biopsies for pathological anatomy.

And since the endoscopy is a torture test, painful and costly, our study aimed to the evaluate serum CRP levels and feacal Calprotectin in both IBS and IBD patients.

And evaluate the diagnostic ability of both markers to discriminate between the clinical cases.

The study included 198 patients, they were divided into 4 groups, according to their endoscopy and pathological anatomy results.

The hs-CRP levels were determined using turbidimetry and the feacal calprotectin was detected in the half quantitive assay.

The results were analyzed by canonical discriminate analysis.

Feacal Calprotectin was able to discriminate 97.5% of the cases, while the CRP was able to discriminate between Crohn's disease and Ulcerative Colitis.

And due to its higher level in Crohn's disease, it has twice the importance to diagnose Crohn's disease.

In conclusion, we can rely on the feacal calprotectin as marker that refers the inflammatory state, and if its level was above 15 µg/g, the patient should undergo colon endoscopy.

While CRP is a complement marker.